Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
An increasing number of synthetic cannabinoids have become available on the black market in recent years, and health professionals have seen a corresponding increase in use of these compounds among patients with psychiatric disorders. Unfortunately, there is almost no research available in the literature on this topic, and what little exists is based on case reports of individuals without psychiatric disorders. Synthetic cannabinoids are functionally similar to, but structurally different from, delta-9-tetrahydrocannabinol, the active principle in cannabis, and are problematic for many reasons. The psychotropic action of synthetic cannabinoids in patients with schizophrenia is unpredictable, with very diverse clinical presentations. These drugs can be much more potent than delta-9-tetrahydrocannabinol, they are readily available and difficult to detect. The gold standard for identification of synthetic cannabinoids is gas chromatography with mass spectrometry, but even this is difficult because new formulations of these designer drugs are constantly emerging. In this manuscript, we provide an overview and discussion of synthetic cannabinoids and present four cases of patients with synthetic cannabinoid intoxication who were hospitalized in our intensive psychiatric unit at the time of intoxication. All patients had a history of schizophrenia and had been hospitalized several times previously. While hospitalized, they smoked an unknown substance brought in by a visitor, which was then confirmed using gas chromatography with mass spectrometry to be the synthetic cannabinoid AM-2201. Our patients experienced predominantly psychiatric adverse clinical effects. We observed the appearance of new psychotic phenomena, without exacerbation of their previously known psychotic symptoms, as well as the occurrence or marked worsening of mood and anxiety symptoms. Despite several similar reactions, and even though they ingested the same exact substance, the clinical picture differed markedly between individual patients. We assume that the acute effects of synthetic cannabinoids in patients with schizophrenia would be different from those in persons without psychotic disorders. The reasons for this difference could be the actual symptomatology of the presenting disorder, the impact of psychopharmacotherapy, individual patient differences and probably many, as yet unknown, factors. The long-term consequences of synthetic cannabinoid use on preexisting psychotic disorders are unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Esposito, S., Deventer, K., Dumoulin, M., & Van Eenoo, P. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1418 · Cited by 133
Cited by
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
“Similarly, SC intake has been associated with the occurrence of florid/acute transient psychosis, relapse/ worsening of a pre-existing psychosis, persisting psychotic disorders/“spiceophrenia” (6), and manic-like symptoms or relapse of pre-existing bipolar disorder (58,59).”
BackgroundNew/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review
de Oliveira, M. C., Vides, M. C., Lassi, D. L. S., Torales, J., Ventriglio, A., Bombana, H. S., Leyton, V., Périco, C. D. A.-M., Negrão, A. B., Malbergier, A., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13070990 · Cited by 61
“Author, Year, Country Synthetic Cannabinoid N (Sample); Age (Mean); Gender (M:F); Setting (O: Outpatient; I: Inpatient; ED: Emergency Department) Adverse Effects Lapoint et al., 2011, USA [34] JWH-018 1; 48; 1:0; ED Seizures, supraventriculartachycardia Schneir et al., 2011, USA [35] JWH-018, JWH-073 2; 21; 0:2; ED An…”
Metadata
- Authors
- Celofiga, A., Koprivsek, J., & Klavz, J.
- Venue
- Journal of Dual Diagnosis
- Publisher
- Informa UK Limited
- Published
- 2014-07-03
- Volume
- 10
- Issue
- 3
- Pages
- 168-173
- ISSN
- 1550-4263 (ISSN-L)
- 1550-4271
- OpenAlex
- W2072475603
- Cited by
- 54
- References
- 1
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series. https://app.cochat.ai/papers/10.1080/15504263.2014.929364
- The paper
- Celofiga, A., Koprivsek, J., & Klavz, J. (2014). Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2014.929364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.